Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.

source https://finance.yahoo.com/m/d79fb824-955e-3f7a-94b6-fc225e4efdf4/how-this-pharma-stock-could.html?.tsrc=rss